Klaus Schollmeier is an advisor to the Pharma/Biotech industry and member of the board/chairman of several Biotech companies including Tacalyx (Germany), Anergis Pharma (Switzerland), Affiris Pharma (Austria) and Eternygen (Germany). He also advises and mentors a number of start-up companies in Europe as Entrepreneur in residence and business angel, including BASF’s company builder Chemovator.

Mr Schollmeier was Chief Executive Officer of SuppreMol, Munich/Germany from 2013 until 2015, when the company was sold to Baxalta. Prior to that, he served as CEO of Santhera, Basel/Switzerland, from 2004 to 2011 and chairman of the board of Santhera until 2013. Mr Schollmeier joined Graffinity Pharmaceuticals AG, Heidelberg/Germany as CEO in 2003 and merged the company with MyoContract AG, Basel/Switzerland in 2004 to form Santhera.

Prior to joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. 

Mr Schollmeier holds a PhD in biology from the University of Düsseldorf, Germany, and in 1991, he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.